Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

June 27, 2025

To whom it may concern

Company name: Qol Holdings Co., Ltd.
Name of representative: Takashi Nakamura, Representative Director and President
(Securities code: 3034, TSE Prime Market)
Inquiries: Hiromoto Shirakuni, General Manager of Public Relations Dept.
(Telephone: +81-(0)3-6430-9060)

Matters Concerning Controlling Shareholders

Qol Holdings Co., Ltd. (hereinafter "the Company") hereby announces that matters concerning controlling shareholders of the Company are as described below.

1. Trade name of parent company, controlling shareholder (excluding parent company), or other affiliated company

(As of March 31, 2025)

Name	Attribute	Ratio of voting rights held (%)			Financial instruments exchange, on which the issued shares are listed
		Voting rights directly held	Voting rights subject to aggregation	Total	
MEDIPAL HOLDINGS CORPORATION	Other affiliated company	20.1	2.9	23.0	Prime Market of Tokyo Stock Exchange

2. Positioning of the Company in the corporate group centering on the parent company, and the relationships between other listed companies and the parent company.

MEDIPAL HOLDINGS CORPORATION is our largest shareholder of the Company, holding 23.0% of our shares (voting rights). The Company maintains a close working relationship with MEDIPAL HOLDINGS CORPORATION Group. In addition, the Company's consolidated subsidiaries purchase goods from MEDIPAL HOLDINGS CORPORATION Group under the same conditions as business partners that do not have a capital relationship with the Company. The Company is not subject to any business restrictions from the parent company and conducts its business activities independently. In addition, the Company believes that it has a certain degree of independence from the parent company, as transactions with the corporate group centering on the parent company are conducted under the same economic terms as transactions with business partners that have no relationship with the Company.

3.Matters concerning transactions with controlling shareholder

（1） Transactions between the Company and related parties
Not applicable.

(2) Transactions between the Company's consolidated subsidiaries and related parties

（April 1, 2024 to March 31, 2025）

Attribute	Name of company	Location	Capital (in millions of yen)	Business description	Ratio of voting rights held (%)
Subsidiaries of other affiliated companies	MEDICEO CORPORATION	Chuo-ku, Tokyo	100	Pharmaceuticals Wholesale	—

Relationship with related party	Transaction details	Transaction amount (in millions of yen)	Description	Final balance (in millions of yen)
Pharmaceutical and other suppliers of the Company's subsidiary	Procurement of pharmaceuticals and other.	43,969	Accounts payable	9,891

(Note)

(1) Consumption tax is not included in the transaction amount, and consumption tax is included in the balance at the end of the period.

(2) Transaction conditions and policy for determining transaction conditions, etc.

1. It is conducted under the same conditions as business partners who do not have a relationship with the Company's subsidiaries.
2. MEDICEO CORPORATION is a wholly owned subsidiary of MEDIPAL HOLDINGS CORPORATION which is the Company's major corporate shareholder (Ownership ratio: 23.0%, of which indirect ownership ratio: 2.9%).

- End -